On 7 December, Marlène Hekman, theme Urological cancers, has defended her PhD thesis entitled “Tumor-targeted imaging of cancer with radiolabeled and fluorescently labeled antibodies”.Based on her excellent thesis and performance during the defense, the doctorate was awarded with the distinction 'cum laude'.
The aim of the studies described in this thesis was the clinical translation of targeted imaging using radiolabeled and fluorescently labeled antibodies. By conjugating a radionuclide or a fluorescent molecule to an antibody, a tumor-targeting imaging tracer is created that can be used to visualize tumors. The preclinical studies have shown the additional value of dual-modality imaging in the detection of small tumors in models for colorectal and ovarian cancer. Next, two clinical applications of targeted imaging with girentuximab in clear cell renal cell carcinoma (ccRCC) were described; as a diagnostic tool for ccRCC (89Zr-girentuximab) and for intraoperative guidance of ccRCC resection (111In-girentuximab-IRDye800CW).This thesis shows that sensitive non-invasive or intraoperative imaging techniques can improve the management of patients with cancer. Ultimately, the combination of several intraoperative techniques may deliver the best information to lead patient management in a personalized fashion.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more